Drug intelligence / Profile preview

WST03

Development stage: Unknown
Lead developer: Shanghai Sine
Modality: Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
Administration: Topical

Overview

WST03 is an investigational live biotherapeutic product (LBP) developed by Shanghai Sine Pharmaceutical Laboratories, a subsidiary of Shanghai Pharma, for the treatment of bacterial vaginosis (BV). It consists of a specific strain of *Lactobacillus crispatus*, a commensal bacterium that is a hallmark of a healthy vaginal microbiome. WST03 is designed to be administered intravaginally to replenish the *Lactobacillus* population, which is typically depleted in patients suffering from BV. By colonizing the vaginal epithelium and producing lactic acid, hydrogen peroxide, and other antimicrobial substances, WST03 helps restore a low vaginal pH and inhibits the overgrowth of anaerobic pathogens such as *Gardnerella vaginalis*. As a Class 1 biological new drug in China, it represents a targeted approach to microbiome restoration rather than traditional antibiotic treatment.

Other names: Lactobacillus crispatus vaginal capsule

Beyond the preview

Go deeper on WST03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WST03.

Explore the full profile